Admera Health Supercharges Sequencing Capabilities with Addition of a Second Illumina NovaSeq X Plus
Admera Health, a premier provider of advanced next-generation sequencing and bioinformatics multi-omic services, is pleased to announce the acquisition of their second NovaSeq X Plus platform at their lab in South Plainfield, New Jersey. Admera Health was the first commercial company in the United States to onboard the NovaSeq X Plus in March 2023, and is delighted to expand its capabilities with a second instrument, further supporting researchers with cost-efficient, high-throughput tools with rapid turnaround.
Accelerating Research With Enhanced Capacity
The addition of a second NovaSeq X Plus represents a major leap forward in their ability to support researchers with diverse sequencing needs. By significantly increasing our throughput, they can continue to process a greater volume of samples in less time, empowering researchers to advance their studies more rapidly with high-throughput capabilities. This enhanced capacity benefits a wide range of applications, including:
Genomic discovery: Maximize cost savings and obtain deeper sequencing to discover rare variants, understand complex diseases, and answer biological questions.
RNA-seq: Use the NovaSeq X Plus platform to gain deeper insights into gene expression patterns and alternative splicing events.
Epigenomics: Explore regulatory mechanisms that shape cellular function with greater depth for more advanced insights.
Single-cell sequencing: With ultra-high throughput capabilities of the NovaSeq X Plus, run more cells per sample with technologies from Parse Biosciences Evercode™ WT Penta 10x Genomics Chromium Single Cell.
Spatial Transcriptomics: Accelerate the discovery of complex spatial gene expression patterns and more. This enhanced capacity empowers researchers to explore biological processes with greater resolution.
Rapid premade library sequencing: Get ready to accelerate your research like never before. Doubling the sequencing power means data is delivered at market-leading speeds, putting groundbreaking dsicoveries withing reach faster than ever before.
Our Commitment to Innovation
Admera Health is dedicated to staying at the forefront of genomic technologies. This investment in sequencing infrastructure underscores their commitment to providing clients with the most advanced tools and services available.
Featured in a recent Illumina article, Admera Health is recognized in their strategic role of the of the NovaSeq X Plus in expanding capabilities. This powerful sequencer allows Admera to significantly reduce workflow bottlenecks and create cost efficiencies, ultimately increasing output. The article emphasizes new capabilities that are possible with the NovaSeq X plus, including newborn screening initiatives and clinical trials.
Admera Health’s acquisition of another NovaSeq X plus underscores their commitment to embracing cutting-edge technologies and fostering innovation within the genomics field. This dedication is further exemplified by their acquisition of BioEcho Life Sciences to enhance their sequencing services and proactive testing of Illumina’s software updates for performance improvements. Admera Health values its strong partnership with Illumina, recognizing the importance of collaboration and a shared scientific mindset in advancing capabilities.
Technical Highlights of the NovaSeq X Plus
Enhanced Optics and Fluidics: The NovaSeq X Plus features advanced optics and fluidics systems, optimizing signal detection and minimizing reagent consumption.
Scalability and Flexibility: The platform offers unparalleled scalability and flexibility, accommodating a wide range of applications and sample types.
Reduced Turnaround Time: By utilizing a second NovaSeq X Plus sequencing platform, we reduce our already quick turnaround times, with the ability to deliver sequencing data within 5 business days.
The Future of Sequencing at Admera Health
Admera Health is looking forward to the opportunities this expansion brings. They are committed to working closely with research partners to leverage the power of multiple NovaSeq X Plus sequencers and accelerate discoveries. Sequencing on the NovaSeq X Plus 1.5B, 10B, and 25B flow cells are available at Admera Health with faster turnaround times and more cost efficiency than ever. Inquire with the team to align your next sequencing project and to learn more about how their sequencing capabilities can support diverse research applications.